1 / 23

Chronic Kidney Disease

Medication review Warren Prokopiw Pharmacy Resident 2011-12. Chronic Kidney Disease. Outline. Case intro Renal failure issues Hypertension, lipids, glucose, anemia Renal bone disease, potassium, acid-base GI Disorders, nutrition, puritis, gout Nervous system disorders

ursala
Télécharger la présentation

Chronic Kidney Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Medication review Warren Prokopiw Pharmacy Resident 2011-12 Chronic Kidney Disease

  2. Outline • Case intro • Renal failure issues • Hypertension, lipids, glucose, anemia • Renal bone disease, potassium, acid-base • GI Disorders, nutrition, puritis, gout • Nervous system disorders • Application to case • Questions

  3. Meet Mr Smith • 80 year old gentleman with chronic renal failure eGFR = 20 • Managed at renal clinic • Previous medical history • DM 2 x 15 years • hypertension • osteoarthritis • glaucoma • psoriasis • gout

  4. Current medication list

  5. Hypertension • Common association – 75% of patients • Cause and consequence of CKD • Target is 130/80 – slow decline to target • Medications • ACEI/ARB and CCB • Diuretics - loop, thiazide, combination • Beta blockers (pts < 60) • Second or third line agents • Nitroglycerin, hydralazine, clonidine,

  6. Hyperlipidemia • High prevalence in CKD patients • Major risk factor for progression of disease • Targets • LDL < 2.0; TC/HDL ratio < 4.0 TG < 10 • Medications • Statins for high LDL/low HDL • Gemfibrozil or nicacin for elevated TG

  7. Diabetes • Risk factor for CKD and cardiovascular events • Tight control reduces diabetic nephropathy • HbA1C < 7.0% Fasting glucose 4-7 mmol/L • Medications • Gliclazide over glyburide • Avoid metformin when GFR < 30 ml/min • Part of multifactorial strategy promoting BP control and CV risk

  8. Anemia • Due to erythropoetin deficiency • Target 110 g/L – start if Hg < 100 g/L • Medications • Erythropoetin and darbepoetin • Takes 64 days to reach new steady state • Reassess dose in 4 weeks • Require adequate iron, folic acid and B12 stores for synthesis

  9. Iron Supplements • Targets - Tsat > 20% Ferretin > 100 ng/ml. • Oral - preferred • ferrous fumarate • ferrous gluconae • ferrous sulfate • IV – when patients fail/not tolerate oral • iron gluconate • iron sucrose • iron dextran

  10. Renal Bone Disease • Reduced renal function → PO4 retention • Elevated PO4 → lowered Ca++ → less activation of Vit D → less Ca++ absorption → direct binding PO4 to Ca++ in blood • Parathyroid gland stimulated • ↑ renal Ca++ and PO4 reabsorption • ↑ Ca++ mobilization from bone

  11. RBD Prevention • Goal – keep in normal range • PO4 0.75-1.4 mmol/L, Ca++ 2.2-2.5 mmol/L • Dietary PO4 restriction • PO4 Binder if no hypercalcemia • Calcium carbonate, calcium acetate, aluminum hydroxide, sevelamer, lanthanum, cinacalet • Ca++ supplement if hypocalcemic

  12. RBD Prevention • Vitamin D supplement if PTH > 53 pmol/L • Alfacalcidol, calcitriol • Used TIW pluse therapy • Reduce Ca++ and Vit D if hypercalcemia

  13. Hyperlakemia • Potassium usually 90% renally eliminated • In CRF, the DCT compensates with increased secretion • Aldosterone plays and important role • Further decrease in renal function • Increased secretion by the colon • Management • Dietary potassium restriction – avoid constipation • Monitor if on ACEI, avoid K+ sparing diuretics • Sodium polystyrene sulfonate • dialysis

  14. Acid Base • Renal PO4 excretion provides buffer for elimination of H+ ions • ↓ PO4 excretion → metabolic acidoisis • Medication • Sodium bicarbonate • Sodium citrate • Monitor water balance due to sodium content

  15. GI Disorders • Most CDK patients are diabetic • Diabetic gastopariesis • Taking high calcium loads • Constipation • Medications • Prokinetics • Domperidone and metoclopramide • Laxatives • Docusate sodium, Senna, Lactulose • AVOID Fleet enemas and Fruitlax

  16. Nutritional Deficiencies • Dialysis removes water soluble vitamins and zinc • Deficient in vitamin B1, B2, B6, B12, niacin, pantothenic acid, niacinamide, folic acid and vitamin C • Medication • Replavite • Zinc Supplement

  17. Puritis • Occurs in up to 86% of dialysis patients • Cause unknown • Dry skin, hyper PTH, increased Vit A and histamine • Medications • Hydroxyzine • Diphenhydramine • 10% uremol in glaxal base

  18. Gout • Renal failure leads to hyperuricemia • Diuretics used for volume overload compound problem • Medications • Allopurinol – prevention • Colchicine – short term treatment • prednisone

  19. Nervous System Disorders • Affect 50% of patients with EDRD • uremic polyneuropathy is axonal in nature • Restless legs syndrome • Occurs in 50% of ESRD patients due to uremia • Medictions • sinemet, clonidine, clonazepam

  20. Nervous System Disorders • Leg cramps • May occur during dialysis • Associated with large volume draws • Medication • Quinine • Neuropathic pain • Typical pain agents • Desipramine, nortryptyline, carbamazepine, gabapentin

  21. Current medication list

  22. Questions

More Related